For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Immune Design Corp.

USPTO Granted Patents = 16

CIPO Patents = 2

EPO Patents = 11

Forward Citations = 79

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Jan Henrik Ter Meulen (7 out of 9 patents)

Thomas W Dubensky, Jr (5 out of 53 patents)

Peter Lars Aksel Berglund (4 out of 4 patents)

4. Carlos V Paya Cuenca (4 out of 4 patents)

5. Scott H Robbins (4 out of 4 patents)

6. Christopher James Nicolai (3 out of 4 patents)

7. Nancy Ann Hosken (3 out of 24 patents)

8. Margaret Dow Moore (3 out of 19 patents)

9. Semih Ullah Tareen (3 out of 9 patents)

10. Tinglan Tina Albershardt (1 out of 1 patent)

11. Neal Van Hoeven (1 out of 8 patents)

12. Jacob Freeman Archer (1 out of 3 patents)

13. Tsai-Yu Lin (1 out of 1 patent)

14. Jin Zhong Li (1 out of 1 patent)

15. Derek D Sloan (1 out of 1 patent)

16 patents: Sort by Forward Citations

1. 11365230 - Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof (2022-06-21),

2. 11135283 - Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids (2021-10-05),

3. 10993956 - GLA monotherapy for use in cancer treatment (2021-05-04),

4. 10584356 - Multigenome retroviral vector preparations and methods and systems for producing and using same (2020-03-10),

5. 10391164 - Vaccines for HSV-2 (2019-08-27),

6. 10391157 - Materials and methods for producing improved lentiviral vector particles (2019-08-27),

7. 10342815 - GLA monotherapy for use in cancer treatment (2019-07-09),

8. 10179919 - Multigenome retroviral vector preparations and methods and systems for producing and using same (2019-01-15),

9. 9895435 - Vaccines for HSV-2 (2018-02-20),

10. 9713635 - Materials and methods for producing improved lentiviral vector particles (2017-07-25),

11. 9555099 - Vaccines for HSV-2 (2017-01-31),

12. 9044420 - Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses (2015-06-02),

13. 8962593 - GLA monotherapy for use in cancer treatment (2015-02-24),

14. 8957047 - GLA monotherapy for use in cancer treatment (2015-02-17),

15. 8323662 - Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein (2012-12-04),

Immune Design Corp. is a clinical-stage immunotherapy company focused on developing novel therapies that use the immune system to fight diseases. Their innovative pipeline utilizes multiple immune modulating approaches, including intratumoral therapies, systemic TLR agonists, and combinations of therapies to unlock the potential of the immune system in treating various types of cancer and infectious diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

16 Patents

#109 in Seattle, WA

#404 in Washington

#19,312 in US

#36,684 in the World

Seattle, WA, United States of America

Immune Design Corp.

Forward Citations = 79

16 inventors:

Jan Henrik Ter Meulen (7 out of 9 patents)

Thomas W Dubensky, Jr (5 out of 53 patents)

Peter Lars Aksel Berglund (4 out of 4 patents)

4. Carlos V Paya Cuenca (4 out of 4 patents)

5. Scott H Robbins (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…